Natalie Grover

(Reuters) - Sarepta Therapeutics Inc said patients trialing its muscle wasting disorder drug showed an accelerated decline in walking ability after nearly three years of use, sending the company's shares...

By Natalie Grover (Reuters) - Geron Corp said the U.S. Food and Drug Administration had lifted a partial clinical hold on a study testing its sole drug as a treatment...

By Natalie Grover (Reuters) - BioCryst Pharmaceuticals Inc's oral drug to prevent a hereditary disorder characterized by abnormal swelling was effective in reducing attacks, sending the drugmaker's shares up as...

By Natalie Grover (Reuters) - Israel-based drugmaker Kamada Ltd said its experimental drug failed in a key trial to treat an inherited condition that raises the risk of lung and...

By Natalie Grover (Reuters) - Acorda Therapeutics Inc said the Food and Drug Administration rejected its nasal form of the current standard therapy for epilepsy patients who experience repetitive seizures....

By Natalie Grover (Reuters) - Amicus Therapeutics Inc said its experimental drug significantly reduced the abnormal accumulation of fat in body cells related to a rare genetic disorder that could...

(Reuters) - Spectrum Pharmaceuticals Inc said it expects to seek U.S. marketing approval for its blood cancer drug in the third quarter, after the treatment was shown to be safe...

(Reuters) - Spectrum Pharmaceuticals Inc said it expects to seek U.S. marketing approval for its blood cancer drug in the third quarter, after the treatment was shown to be safe...

(Reuters) - A U.S. District Court judge on Tuesday stopped Massachusetts from implementing a ban on the sale of Zogenix Inc's prescription painkiller Zohydro, saying federal law superseded the state's...